🇺🇸 FDA
Pipeline program

I-131-CLR1404

DCL-14-002

Phase 1 small_molecule completed

Quick answer

I-131-CLR1404 for Multiple Myeloma is a Phase 1 program (small_molecule) at Cellectar Biosciences with 1 ClinicalTrials.gov record(s).

Program details

Company
Cellectar Biosciences
Indication
Multiple Myeloma
Phase
Phase 1
Modality
small_molecule
Status
completed

Clinical trials